| Autor: |
Lokman EF; Endocrine and Metabolic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health, Selangor, Malaysia., Bugam SH; Downstream Technology Division, CRAUN Research Sdn. Bhd., Sarawak, Malaysia., Ibrahim AS; Downstream Technology Division, CRAUN Research Sdn. Bhd., Sarawak, Malaysia., Yunus N; Downstream Technology Division, CRAUN Research Sdn. Bhd., Sarawak, Malaysia., Mansor F; Endocrine and Metabolic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health, Selangor, Malaysia., Balasubramaniam V; Nutrition Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health, Selangor, Malaysia., Mohamad KM; Endocrine and Metabolic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health, Selangor, Malaysia., Md Lazim R; Endocrine and Metabolic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health, Selangor, Malaysia.; Downstream Technology Division, CRAUN Research Sdn. Bhd., Sarawak, Malaysia., Awang Seruji AZR; Downstream Technology Division, CRAUN Research Sdn. Bhd., Sarawak, Malaysia. |
| Abstrakt: |
Introduction: The beneficial effects of resistant starch (RS) consumption on health in terms of reducing postprandial hyperglycaemia are evident. However, the potential of local Sarawak sago RS in regulating glucose has not been extensively studied. Objectives: This study aims to identify glucose-lowering effects of Sarawak sago RS, namely native (RS2) and chemically modified (RS4). Methodology: An oral glucose tolerance test (OGTT) was performed before and after 1 month treatment with sago RS2 and RS4 in spontaneously type 2 diabetes (T2D), Goto-Kakizaki (GK) rat. The mechanisms involved were further explored by screening the in vitro inhibitory activities of α-glucosidase and dipeptidyl peptidase (DPP)-IV. Histopathology examination for pancreas, kidney and liver tissues was done in response to sago RS intake using haematoxylin and eosin (H&E) staining. Results and discussion: The incremental area under the curve (iAUC) for blood glucose in RS-treated groups was decreased and significant in RS2-treated group ( p < 0.05). Improved iAUC for insulin and higher glucagon-like peptide (GLP-1) levels were observed in all RS-treated groups ( p < 0.05). Both sago RS may have potential roles in regulating glucose via α- glucosidase and DPP-IV inhibitory activities by reducing intestinal glucose absorption. For histopathology, although insignificant, sago RS2 and RS4 attenuated lesion scores of pancreatic tissue whereas the liver and kidney tissues significantly showed lesser lesion scores compared to the control diabetic group suggesting the potential of RS in reducing cell degeneration. Conclusion: Findings of this study indicates that RS2 showed greater glucose-lowering effect when compared to RS4, thus the therapeutic potential in the T2D management should be further explored. |
